{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Interrelationship of Lipid and Glucose Metabolism Disorders Exemplified in Agents that Favorably Influence Both - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"HY7D5jGwfV\"><a href=\"https:\/\/themedicalxchange.com\/en\/2012\/12\/04\/2012-scientific-sessions-of-the-american-heart-ass\/\">Interrelationship of Lipid and Glucose Metabolism Disorders Exemplified in Agents that Favorably Influence Both<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2012\/12\/04\/2012-scientific-sessions-of-the-american-heart-ass\/embed\/#?secret=HY7D5jGwfV\" width=\"600\" height=\"338\" title=\"&#8220;Interrelationship of Lipid and Glucose Metabolism Disorders Exemplified in Agents that Favorably Influence Both&#8221; &#8212; The Medical Xchange\" data-secret=\"HY7D5jGwfV\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/12\/AHA_2335_Figure_1a_EN.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Los Angeles \u2013 In patients with dyslipidemia and impaired fasting glucose (IFG), newly-presented data demonstrate that adding a bile acid sequestrant into the treatment mix will address both metabolic disorders simultaneously. The results of the randomized placebo-controlled trial, presented at the 2012 AHA, contribute significantly to cardiovascular (CV) risk management because of the frequency with which hyperlipidemia and impaired glucose metabolism co-exist. The growing population of individuals in Canada who require treatment of multiple CV risks, best illustrated by the epidemic of metabolic syndrome that is accompanying rising rates of obesity, has led to complicated risk management schemes that may be simplified by using therapies with multiple favorable effects. In the study, the addition of a bile acid sequestrant was well tolerated and accepted by patients."}